March 14, 2026 · Form 4 insider transaction
Patel Naimish bought 8,125 shares of CRISPR Therapeutics AG, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.; Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.; Includes 592 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.